Ocular Therapeutix, Inc.

OCULNASDAQ • USD
6.96 USD
↘ 0.33 (4.53%)AT CLOSE (03:59 PM EDT)
7.06
↗ 0.10 (1.44%)
POST MARKET (AS OF 07:34 PM EDT)
Post Market
AS OF 07:34 PM EDT
7.06
↗ 0.10 (1.44%)
🔴Market: CLOSED

OCUL is currently priced at $6.96. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". Notable factors include negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics place OCUL at a fair price relative to peers.

Technical & fundamental data as of Oct 2, 2026.

Open?$7.40
High?$7.43
Low?$6.94
Prev. Close?$7.29
Volume?5.0M
Avg. Volume?3.0M
VWAP?$7.08
Rel. Volume?1.67x
Bid / Ask
Bid?$6.02 × 100
Ask?$6.97 × 100
Spread?$0.95
Midpoint?$6.49
Valuation & Ratios
Market Cap?1.5B
Shares Out?219.6M
Float?190.3M
Float %?86.9%
P/E Ratio?N/A
P/B Ratio?2.94
EPS?-$1.37
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Employees
325
Market Cap
1.5B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2014-07-25
Address
14 CROSBY DRIVE, 3RD FLOOR
BEDFORD, MA 01730
Phone: 781-357-4000
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
68
Momentum?
65
Short Sent.?
14
Piotroski F-Score?3/9Weak
Altman Z-Score?2.90Grey
Confidence?61%Moderate
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?15.73%High
Short Interest?29.9M
Days to Cover?14.2
Free Float190.3M
Avg Daily Volume2.1M
Settlement Date2026-09-15
Financial Health
Current Ratio?13.11Strong
Quick Ratio?13.03Strong
Cash Ratio?12.17Strong
Debt/Equity?0.14Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
57
2.94CHEAP▾
P/S?
Peers
100
S&P
3
29.36HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.3CHEAP▾
EV/Sales?
Peers
100
S&P
3
19.26HIGH▾
Returns & Efficiency
ROE?
S&P
3
-58.0%WEAK▾
ROA?
S&P
3
-44.9%WEAK▾
Cash Flow & Enterprise
FCF?$-255100000
Enterprise Value?$1.0B
Fundamentals ratios updated end of day